Who is sponsoring NCT05454540?

NCT05454540 is sponsored by I.R.C.C.S. Fondazione Santa Lucia.

What drugs are being tested in NCT05454540?

Interventions in NCT05454540: REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION.

What condition does NCT05454540 study?

NCT05454540 studies Alzheimer Disease.

Is NCT05454540 still recruiting?

NCT05454540 is currently completed. Last updated 18 October 2024.

Last reviewed 2024-10-18 · How we verify

NCT05454540

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Repetitive TMS of the Posterior DMN in AD

Completed NA Last updated 18 October 2024

What this trial tests

NA trial testing REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION in Alzheimer Disease in 60 participants. Completed in 30 November 2023.

Timeline

1 October 2018

Primary endpoint
30 November 2023

30 November 2023

Quick facts

Lead sponsor	I.R.C.C.S. Fondazione Santa Lucia
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	60
Start date	1 October 2018
Primary completion	30 November 2023
Estimated completion	30 November 2023
Sites	2 locations across Italy

Drugs / interventions tested

REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION

Conditions studied

Alzheimer Disease — all drugs for Alzheimer Disease →

Sponsor

I.R.C.C.S. Fondazione Santa Lucia — full company profile →

Who can join

Adults 30 to 85, any sex, with Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary aim of this project is to investigate the safety and efficacy of repetitive transcranial magnetic stimulation (rTMS) on cognition in patients with mild to moderate Alzheimer's disease. rTMS is considered a safe, well tolerated and relatively cheap treatment. The appealing idea of the intervention is to improve memory by directly modulating the activity of precuneus, key area linked to memory impairment. Patients will be treated with rTMS in two phases: a 2-week intensive phase followed by a maintenance phase for a total of 52 weeks. This project aims to provide a valid treatment to slow the worsening of symptoms and improve quality of life for those with Alzheimer's and their caregivers.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Effects of 52 weeks of precuneus rTMS in Alzheimer's disease patients: a randomized trial.
Koch G, Casula EP, Bonnì S, Borghi I, et al · · 2025 · cited 16× · PMID 40176122 · DOI 10.1186/s13195-025-01709-7
The Potential for Neuromodulation in the Treatment of Alzheimer's Disease: A Review of Clinical Trials.
Jones T, Shalom M, Chalamgari A, Gold J, et al · · 2025 · PMID 40599507 · DOI 10.7759/cureus.85156

Verify or expand the search:

Other trials of REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION

Trials testing the same drug.

NCT03778151 — Repetitive TMS of the Default Mode Network in AD · NA · completed
NCT03456362 — Cerebellar rTMS to Improve Gait Recovery · NA · completed

Other recruiting trials for Alzheimer Disease

Currently open trials in the same condition.

NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting

Other I.R.C.C.S. Fondazione Santa Lucia trials

Trials by the same sponsor.

NCT07257679 — Gentle Touch for Post-Mastectomy Lymphedema · Phase 4 · recruiting
NCT07254377 — Design and Validation of Innovative Strategies Based on Dual-Task Approach · NA · active not recruiting
NCT06420271 — Effects of Cerebellar tACS-iTBS in Ataxia · NA · recruiting
NCT06911671 — EMG Control Assistance Virtual Reality Interface Coupled With Cerebellar-iTBS for Arm Recovery After Stroke (ERICA) · NA · recruiting
NCT07075770 — Novel Personalized Non Invasive Combined Magnetic and Electrical Stimulation of the DMN in Mild AD Patients · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05454540 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by I.R.C.C.S. Fondazione Santa Lucia
Last refreshed: 18 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05454540.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing